The laboratory legend
Survodutide carried one GLP-1 flame and one glucagon flame. The liver chamber grew interested; the canon chamber demanded completed trials.
This bold passage is invented comedy, not scientific or historical fact.
Seeking Canonization · 2020s
Survodutide
The Two-Flamed Petitioner
Boehringer Ingelheim + Zealand Pharma
Survodutide (BI 456906) is an investigational medicine that activates glucagon and GLP-1 receptors. Researchers are studying it for obesity and MASH, a form of metabolic liver disease with inflammation. Phase 3 development is underway; it is not FDA-approved.
ClassificationSeeking Canonization
Evidence summaryInvestigational · not FDA-approved
OriginBoehringer Ingelheim + Zealand Pharma
What the evidence says
Weight-management research
The phase 3 SYNCHRONIZE-2 trial studied adults with overweight or obesity and type 2 diabetes. Boehringer Ingelheim reported positive weight-loss results on October 1, 2026. This is a trial-specific finding, not an approved indication or a head-to-head comparison with other medicines. Sponsor update.
Liver-disease research
A published 48-week phase 2 trial treated 293 participants with biopsy-confirmed MASH and fibrosis. MASH improvement without worsening fibrosis occurred in 47%, 62% and 43% across survodutide groups, versus 14% with placebo. Fibrosis improvement was a separate endpoint. These results do not mean that MASH was cured. Trial paper.
Risks and unresolved questions
In that MASH trial, nausea, diarrhea and vomiting were more common with survodutide: 66%, 49% and 41%, respectively, versus 23%, 23% and 4% with placebo. Serious adverse events occurred in 8% versus 7%. These figures describe that study population and regimen, not everyone who might receive the drug.
Larger and longer studies are needed to clarify the balance of benefits and harms. The separate phase 3 MASH program addresses liver-specific questions. Phase 3 MASH study.
Doctide’s verdict
Keep two ledgers: one for weight, one for liver disease. A favorable entry in either cannot erase side effects or fill in outcomes the trial never measured.
Where the real story begins
Known earlier as BI 456906, survodutide is being developed through Boehringer Ingelheim and Zealand Pharma. Its phase 2 obesity trial was published in 2024, followed by phase 3 development. Separate liver-disease studies examine outcomes beyond bodyweight. Historical source.
Boehringer Ingelheim + Zealand Pharma · 2020s
Before you share the headline
Is this the same as retatrutide?
No. Survodutide targets glucagon and GLP-1 receptors; retatrutide also targets GIP. Receptor counts do not establish which medicine is better.
Does phase 3 mean approval is next?
No. It describes a stage of testing, not a guaranteed outcome or approval date. Survodutide remains investigational.
Sources
Evidence and source review: October 10, 2026. Sponsor announcements are identified separately from published trial papers. Clinical development does not establish approval.
- Randomized phase 2 obesity trial — 2024
- NEJM: phase 2 randomized MASH and fibrosis trial — 2024
- Boehringer Ingelheim: SYNCHRONIZE-2 phase 3 update — October 1, 2026
- Sponsor trial record: phase 3 MASH study NCT06632444
- Zealand Pharma: development background
Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.
Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.
Follow the research journey
Join Subject One for six short chapters, from laboratory and animal studies to human trials and today’s evidence.
Read the Survodutide journey →